Waters Corporation
NYSE:WATMedical - Diagnostics & Research
-$0.57 today
- Market cap
- $45.81B
- Beta
- 1.20
- P/E (TTM)
- 65.2
- EPS (TTM)
- $5.47
Volume 0.73M
Average 1.03M
WAT Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Waters CorporationNYSE: WAT
Research & Development · Q2 FY2026 · quarter ended Jul 2026
Research & development growth accelerates
Q2 FY2026 research & development of $122M rose 151.3% year over year, ahead of the +71.7% change in trailing-twelve-month research & development. Sequentially, it rose 27.1% from the prior quarter. Over 3 fiscal years it compounded at +3.5% a year.
Context
- Research & development amounted to 6.2% of revenue in FY2025, unchanged from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +151.3% holds above the trailing-twelve-month pace of +71.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 195.18M USD
- Year-over-year change
- +6.6%
- 4-year CAGR
- +3.8%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 195.18M | +6.6% |
| FY2024 | 2024-12-31 | 183.03M | +4.6% |
| FY2023 | 2023-12-31 | 174.95M | -0.7% |
| FY2022 | 2022-12-31 | 176.19M | +4.7% |
| FY2021 | 2021-12-31 | 168.36M | — |
Research & Development vs competitors
How WAT compares with its peers on the latest reported figures
- WAT's LTM Jul 2026 research & development of $321.75M is the 5th highest of the 7 companies compared; the peer median is $439.25M.
- Its year-over-year change of +71.7% is the highest of 7, against a peer median of +4.7%.
- Research & development amounts to 6.9% of revenue for WAT, versus a peer median of 6.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.67B | +4.2% | +1.5% | 6.5% | |
| LTM Sep 2026 | $1.41B | -0.7% | -1.7% | 3.0% | |
| LTM Jul 2026 | $485M | +8.5% | -0.9% | 6.6% | |
| LTM Jun 2026 | $393.5M | -1.6% | +18.8% | 11.2% | |
| LTM Jul 2026 | $321.75M | +71.7% | +3.5% | 6.9% | |
| LTM Jul 2026 | $215.83M | +5.2% | -0.9% | 7.4% | |
| LTM Jun 2026 | $208.01M | +7.9% | +4.0% | 5.0% | |
| Peer median (excluding WAT) | $439.25M | +4.7% | +0.3% | 6.6% | |
Competitors are the stored peer set for WAT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.79B | 2.97B | 2.96B | 2.96B | 3.17B |
| Cost of Revenue | 1.16B | 1.25B | 1.2B | 1.2B | 1.34B |
| Gross Profit | 1.63B | 1.72B | 1.76B | 1.76B | 1.83B |
| Gross Margin | 58.5% | 58.0% | 59.6% | 59.4% | 57.8% |
| Research & Development | 168.36M | 176.19M | 174.95M | 183.03M | 195.18M |
| Selling, General & Admin | 626.97M | 658.03M | 736.01M | 690.15M | 740.27M |
| Operating Expenses | 807.63M | 850.38M | 943.52M | 931.83M | 935.45M |
| Depreciation & Amortization | 131.68M | 130.42M | 165.91M | 191.83M | 206.24M |
| EBITDA | 982.81M | 1.02B | 1B | 1.04B | 1.01B |
| EBITDA Margin | 35.3% | 34.2% | 33.9% | 35.0% | 32.0% |
| Operating Income | 821.71M | 873.4M | 817.68M | 826.35M | 893.22M |
| Operating Margin | 29.5% | 29.4% | 27.7% | 27.9% | 28.2% |
| Interest Income | 12.22M | 11.02M | 16.62M | 17.42M | 7.39M |
| Interest Expense | 44.94M | 48.8M | 98.86M | 89.68M | 69.55M |
| Other Income / Expenses | (15.51M) | (35.55M) | (81.43M) | (71.49M) | (138.35M) |
| Income Before Tax | 806.19M | 837.85M | 736.24M | 754.87M | 754.88M |
| Pre-Tax Margin | 28.9% | 28.2% | 24.9% | 25.5% | 23.8% |
| Income Tax Expense | 113.35M | 130.09M | 94.01M | 117.03M | 112.25M |
| Net Income | 692.84M | 707.76M | 642.23M | 637.83M | 642.63M |
| Net Margin | 24.9% | 23.8% | 21.7% | 21.6% | 20.3% |
| EPS (Basic) | 11.25 | 11.80 | 10.87 | 10.75 | 10.80 |
| EPS (Diluted) | 11.17 | 11.73 | 10.84 | 10.71 | 10.76 |
| Weighted Avg Shares | 61.58M | 59.99M | 59.08M | 59.33M | 59.51M |
| Weighted Avg Shares (Diluted) | 62.03M | 60.33M | 59.27M | 59.55M | 59.71M |
Waters Corporation
NYSE:WAT
Intrinsic Alpha fair value
Locked
Current Price
$466.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.